共 25 条
[1]
Adams M.A., Anderson M.A., Myles J.D., Khalatbari S., Scheiman J.M., Self-expanding metal stents (SEMS) provide superior outcomes compared to plastic stents for pancreatic cancer patients undergoing neoadjuvant therapy, J Gastrointest Oncol, 3, 4, pp. 309-313, (2012)
[2]
American Cancer Society. What are the key statistics about pancreatic cancer?
[3]
Arguedas M.R., Heudebert G.H., Stinnett A.A., Wilcox C.M., Biliary stents in malignant obstructive jaundice due to pancreatic carcinoma: a cost-effectiveness analysis, Am J Gastroenterol, 97, 4, pp. 898-904, (2002)
[4]
Bakhru M., Ho H.C., Gohil V., Wang A.Y., Ellen K., Sauer B.G., Shami V.M., Kahaleh M., Fully-covered, self-expandable metal stents (CSEMS) in malignant distal biliary strictures: mid-term evaluation, J Gastroenterol Hepatol, 26, 6, pp. 1022-1027, (2011)
[5]
(2012)
[6]
Buxbaum J.L., Biggins S.W., Bagatelos K.C., Inadomi J.M., Ostroff J.W., Inoperable pancreatic cancer patients who have prolonged survival exhibit an increased risk of cholangitis, JOP, 12, 4, pp. 377-383, (2011)
[7]
Chen V., Arguedas M., Baron T., Expandable metal biliary stents before pancreaticoduodenectomy for pancreatic cancer: a Monte-Carlo decision analysis, Clin Gastro and Hepatology, 3, pp. 1229-1237, (2005)
[8]
Conroy T., Desseigne F., Ychou M., Et al., Groupe Tumeurs Digestives of Unicancer
[9]
PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N Engl J Med, 364, 19, pp. 1817-1825, (2011)
[10]
Epstein A.M., Jha A.K., Orav E.J., Liebman D.L., Audet A.M., Zezza M.A., Guterman S., Analysis of early accountable care organizations defines patient, structural, cost, and quality-of-care characteristics, Health Aff (Millwood), 33, 1, pp. 95-102, (2014)